Mevion Medical Systems said today it closed a $150 million financing round with funds slated to support the company’s proton therapy devices and to expand manufacturing.
The round was led by YuanMing Capital and joined by Henan Maisheng Medical Technology and existing investors including HOPU Investments and China Everbright Limited, the Littleton, Mass.-based company said.
Mevion said that funding would be used to support its proton therapy business and to expand the company’s manufacturing capabilities to meet an increased interest in its Hyperscan systems.
Funding will also support the company’s expansion into new global markets, according to a press release.
In April, Mevion Medical Systems announced the launch of its Mevion S250i proton therapy system, touting that the first patient in the world had been treated with the system.
These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.
View Technology Track Featured Sessions
Register today to save. Use code TECHTRACK to save an additional 10%.